The Medical Letter on Drugs and Therapeutics
Treatment of Lyme Disease
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

Most cases of Lyme disease in the US occur between May and September in the Northeastern, Mid-Atlantic and North Central states.

THE DISEASE — Lyme disease in North America is caused by the spirochete Borrelia burgdorferi, which is transmitted to humans by Ixodes scapularis or I. pacificus ticks.1 At least 70-80% of patients infected by B. burgdorferi have the characteristic skin lesion, erythema migrans, which occurs at the site of the tick bite 3-30 days after the tick has detached and expands over days to weeks. The skin lesion may have a bull’s-eye appearance or may be erythematous without central clearing. Fever, headache, malaise, arthralgia or myalgia usually accompany early disease. Multiple (secondary) skin lesions occur in about 15% of patients as a result of spirochetemia. Erythema migrans may go unnoticed because it usually causes little pruritus or ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Treatment of Lyme Disease
Article code: 1342a
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian